VC
CRSP icon

Vivo Capital’s CRISPR Therapeutics CRSP Stock Holding History

Vivo Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-98,511
Closed -$2.31M – 35
2017
Q4 		$2.31M Sell
98,511
-50,367
-34% -$957K 0.5% 26
2017
Q3 		$2.66M Hold
148,878
– – 0.54% 24
2017
Q2 		$2.38M Hold
148,878
– – 0.6% 22
2017
Q1 		$3.24M Hold
148,878
– – 0.95% 17
2016
Q4 		$3.02M Buy
+148,878
New +$2.78M 0.99% 18

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Vivo Capital's CRSP Position: Q1 2018 in Review

Vivo Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2018, closing a stake of 98,511 shares — an estimated $2.31M sold.

Vivo Capital first reported a position in CRSP in Q4 2016 and held it in 5 quarters. The position peaked at $3.24M in Q1 2017. 135 funds tracked by Wall St. Rank hold CRSP as of Q1 2018.

  • Vivo Capital reported no remaining CRISPR Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Vivo Capital sold 98,511 CRISPR Therapeutics shares in Q1 2018, an estimated $2.31M.
  • Vivo Capital first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 5 quarters.
  • Vivo Capital's CRISPR Therapeutics position peaked at $3.24M in Q1 2017.
  • 135 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2018.

Based on Vivo Capital's 13F filing for Q1 2018, filed 15 May 2018.